{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:57:46Z","timestamp":1793969866326,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03770-0","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T09:59:44Z","timestamp":1731578384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts\u2019 perspectives with associated cost-consequence analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Evi","family":"Germeni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacie","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"Suppl 11","key":"3770_CR1","first-page":"2","volume":"14","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14(Suppl 11):2\u201315.","journal-title":"Clin Adv Hematol Oncol"},{"key":"3770_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","volume":"2012","author":"CM Nester","year":"2012","unstructured":"Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematol Am Soc Hematol Educ Program. 2012;2012:617\u201325.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"3770_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/asheducation-2016.1.217","volume":"2016","author":"V Afshar-Kharghan","year":"2016","unstructured":"Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematol Am Soc Hematol Educ Program. 2016;2016(1):217\u201325.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"9","key":"3770_CR4","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1182\/blood.2022017860","volume":"141","author":"F Fakhouri","year":"2023","unstructured":"Fakhouri F, Schwotzer N, Fremeaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome. Blood. 2023;141(9):984\u201395.","journal-title":"Blood"},{"key":"3770_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","volume":"12","author":"K Yan","year":"2020","unstructured":"Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295\u2013305.","journal-title":"Clin Epidemiol"},{"key":"3770_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","volume":"16","author":"C Licht","year":"2015","unstructured":"Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, et al. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol. 2015;16:207.","journal-title":"BMC Nephrol"},{"issue":"11","key":"3770_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1159\/000508920","volume":"144","author":"AI Avila Bernabeu","year":"2020","unstructured":"Avila Bernabeu AI, Cavero Escribano T, Cao Vilarino M. Atypical hemolytic uremic syndrome: New challenges in the complement blockage era. Nephron. 2020;144(11):537\u201349.","journal-title":"Nephron"},{"issue":"6","key":"3770_CR8","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech A, Simon-Tillaux N, Provot F, Delmas Y, Vieira-Martins P, Limou S, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int. 2019;95(6):1443\u201352.","journal-title":"Kidney Int"},{"issue":"1","key":"3770_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12882-020-02190-0","volume":"22","author":"A Gackler","year":"2021","unstructured":"Gackler A, Schonermarck U, Dobronravov V, La Manna G, Denker A, Liu P, et al. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. BMC Nephrol. 2021;22(1):5.","journal-title":"BMC Nephrol"},{"issue":"1","key":"3770_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"JV Walle","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30(1):127\u201334.","journal-title":"J Nephrol"},{"issue":"23","key":"3770_CR11","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"3770_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1053\/j.seminhematol.2018.04.009","volume":"55","author":"F Fakhouri","year":"2018","unstructured":"Fakhouri F, Loirat C. Anticomplement Treatment in atypical and typical hemolytic uremic syndrome. Semin Hematol. 2018;55(3):150\u20138.","journal-title":"Semin Hematol"},{"issue":"1","key":"3770_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ekir.2022.11.006","volume":"8","author":"M Noris","year":"2023","unstructured":"Noris M, Remuzzi G. Every fifteen days forever? Kidney Int Rep. 2023;8(1):4\u20137.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"3770_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40265-021-01481-6","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY, Ravulizumab. A review in atypical Haemolytic Uraemic Syndrome. Drugs. 2021;81(5):587\u201394.","journal-title":"Drugs"},{"issue":"5","key":"3770_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5414\/CN110516","volume":"97","author":"I Tomazos","year":"2022","unstructured":"Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle N, Lommele A, et al. Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: an indirect comparison using clinical trial data. Clin Nephrol. 2022;97(5):261\u201372.","journal-title":"Clin Nephrol"},{"issue":"6","key":"3770_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int. 2020;97(6):1287\u201396.","journal-title":"Kidney Int"},{"issue":"9","key":"3770_CR17","doi-asserted-by":"publisher","first-page":"e230036","DOI":"10.57264\/cer-2023-0036","volume":"12","author":"TJ Mauch","year":"2023","unstructured":"Mauch TJ, Chladek MR, Cataland S, Chaturvedi S, Dixon BP, Garlo K, et al. Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome. J Comp Eff Res. 2023;12(9):e230036.","journal-title":"J Comp Eff Res"},{"issue":"27","key":"3770_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for Invasive Meningococcal Disease among patients receiving Eculizumab (Soliris) despite receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"3770_CR19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","volume":"14","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Fakhouri F, Sartz L, Miller B, Nikolaou V, Cohen D, et al. Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes. Clin Kidney J. 2021;14(9):2075\u201384.","journal-title":"Clin Kidney J"},{"issue":"4","key":"3770_CR20","first-page":"221","volume":"18","author":"J Laurence","year":"2020","unstructured":"Laurence J. Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach. Clin Adv Hematol Oncol. 2020;18(4):221\u201330.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"3770_CR21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","volume":"5","author":"S Chaturvedi","year":"2021","unstructured":"Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv. 2021;5(5):1504\u201312.","journal-title":"Blood Adv"},{"issue":"18","key":"3770_CR22","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137(18):2438\u201349.","journal-title":"Blood"},{"issue":"9","key":"3770_CR23","doi-asserted-by":"publisher","first-page":"e054536","DOI":"10.1136\/bmjopen-2021-054536","volume":"12","author":"S Dunn","year":"2022","unstructured":"Dunn S, Brocklebank V, Bryant A, Carnell S, Chadwick TJ, Johnson S, et al. Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study. BMJ Open. 2022;12(9):e054536.","journal-title":"BMJ Open"},{"issue":"1","key":"3770_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCOUTCOMES.112.967885","volume":"6","author":"LA Curry","year":"2013","unstructured":"Curry LA, Krumholz HM, O\u2019Cathain A, Plano Clark VL, Cherlin E, Bradley EH. Mixed methods in biomedical and health services research. Circ Cardiovasc Qual Outcomes. 2013;6(1):119\u201323.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3770_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"5","key":"3770_CR26","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00467-019-4192-7","volume":"34","author":"G Ariceta","year":"2019","unstructured":"Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol. 2019;34(5):943\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"3770_CR27","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a Single-Arm, open-label trial. Am J Kidney Dis. 2016;68(1):84\u201393.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"3770_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/ckj\/sfy035","volume":"12","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. Clin Kidney J. 2019;12(2):196\u2013205.","journal-title":"Clin Kidney J"},{"issue":"5","key":"3770_CR29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1258\/jrsm.2010.100104","volume":"103","author":"FM Hajjaj","year":"2010","unstructured":"Hajjaj FM, Salek MS, Basra MK, Finlay AY. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med. 2010;103(5):178\u201387.","journal-title":"J R Soc Med"},{"issue":"1","key":"3770_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","volume":"20","author":"J Menne","year":"2019","unstructured":"Menne J, Delmas Y, Fakhouri F, Licht C, Lommele A, Minetti EE, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019;20(1):125.","journal-title":"BMC Nephrol"},{"issue":"12","key":"3770_CR31","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","volume":"23","author":"Y Wang","year":"2020","unstructured":"Wang Y, Johnston K, Popoff E, Myren KJ, Cheung A, Faria C, et al. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. J Med Econ. 2020;23(12):1503\u201315.","journal-title":"J Med Econ"},{"key":"3770_CR32","unstructured":"US Food and Drug Administration. FDA approves first interchangeable biosimilar for two rare diseases. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-interchangeable-biosimilar-two-rare-diseases. May 28, 2024. Accessed June 7, 2024."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03770-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03770-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T10:04:12Z","timestamp":1731578652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03770-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3770"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03770-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4277648\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Biomedical Research Alliance of New York LLC Organizational Review Board and the Weill Cornell Institutional Review Board (Study Protocol: 21-07023785). Written informed consent was obtained from all experts participating in the interviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The consent process involved informing all participants that interviews would form the basis of a publication and that no identifying information would be used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB and JL have received consultancy payments from Alexion Pharmaceuticals in addition to the funding reported here.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"411"}}